Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lung Cancer

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Benzinga

Monday headlines: OAP Rangers fan in tears and Sam Heughan in Glasgow

Here are the main headlines on the Daily Record website today.

Daily Record

Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer

Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The lung cancer symptom which appears in your fingers

Finger clubbing can be an early sign of the illness

Liverpool Echo

Lung cancer patients to get new drug which can double life-expectancy

It means people with aggressive lung cancer can see their life expectancy go from two and half to five years

Wales Online

Finger test may reveal early sign of lung cancer

Sufferers might be able to spot a few early symptoms

Wales Online

Telltale lung cancer sign in your fingertips that could lead to early diagnosis

Lung cancer affects thousands of people and their families across the UK every year.

Daily Record

Read news from The Economist, FT, and more,
with one subscription

Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC

Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells. NM-01 is being investigated in the Phase 2 PELICAN single-arm trial in non-small cell lung cancer (NSCLC) patients.

Benzinga

Lung cancer symptoms: Telltale sign on your fingertips that could lead to early diagnosis

A simple finger test can help diagnose lung cancer. Here's the telltale sign on your fingertips that could be an early symptom of lung cancer as well as the first steps of treatment

Daily Mirror

Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).

Benzinga

Blow to Roche’s Cancer Immunotherapy Prospects as 2nd Trial Fails

Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial. In a study, a combination of tiragolumab and Roche's established Tecentriq drug did not reduce the rate of disease…

Asharq Al-Awsat

Dennis Waterman died after secret lung cancer battle, ex-wife confirms

Dennis Waterman’s second wife Patricia Maynard has paid tribute to the Minder actor who died on Sunday at the age of 74.

Evening Standard

Dennis Waterman died after secret two-year battle with lung cancer, ex-wife confirms

Actor Dennis Waterman, who was best known for his roles in television shows Minder, The Sweeney and New Tricks, died on Sunday afternoon with his fourth wife at his side after a secret two-year battle with lung cancer

Daily Mirror

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Chicago Sun-Times

Dear Abby: Lung cancer killed my mother, and rude people keep asking if she smoked

It’s as if they think people with a tobacco habit deserve to die.

Liverpool Echo

Mum told she had a 'trapped nerve' finds out she has lung cancer

Andrea Fenn started suffering with severe shoulder and spine pain

Benzinga

Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate

Turning Point Therapeutics Inc (NASDAQ:TPTX) entered into an exclusive license agreement with LaNova Medicines Limited to develop and commercialize LM-302, in the U.S. and the rest of the world, excluding Greater China and South Korea. LM-302 is a novel antibody-drug conjugate (ADC) targeting Claudin18.2, a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction,…

Benzinga

Galera Posts Topline Data From Avasopasem Study In Chemoradiotherapy-Induced Esophagitis

Galera Therapeutics Inc (NASDAQ:GRTX) announced topline results from Phase 2a AESOP trial of avasopasem for severe acute radiation-induced esophagitis in lung cancer patients receiving concurrent chemoradiotherapy. Esophagitis is an early side effect of radiation or chemoradiation, causing pain, difficulties in swallowing with potential malnutrition, and dehydration. The trial enrolled 39 patients with unresectable…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

Benzinga

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

Benzinga

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

The Guardian - UK

AI tool accurately predicts tumour regrowth in cancer patients

Exclusive: Tool predicts how likely tumours are to grow back in cancer patients after they have undergone treatment

Benzinga

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Roche Holdings AG's (OTC:RHHBY) mosunetuzumab for relapsed or refractory (R/R) follicular lymphoma (FL). The opinion covers mosunetuzumab for adult patients who have received at least two prior systemic therapies. The CHMP recommendation is based on…

Wales Online

NHS England issues stark warning to anyone who has smoked cigarettes

People most at risk of lung cancer are being urged to attend checks aimed at catching the disease early if they receive an invite

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.